Morningstar

Qiagen NV QGEN

Morningstar Rating

QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology

GlobeNewswire Sep 30, 2024 8:05pm
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays

GlobeNewswire Sep 26, 2024 8:05pm
PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples

GlobeNewswire Sep 25, 2024 8:05pm
QIAGEN and Bode Technology partner to advance use of GEDmatch PRO forensic genetic genealogy database

GlobeNewswire Sep 23, 2024 8:05pm
QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform

GlobeNewswire Sep 18, 2024 8:05pm
QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil’s national screening programs

GlobeNewswire Sep 12, 2024 8:05pm
QIAGEN and Lilly collaborate to support development of a QIAstat-Dx IVD panel that identifies patients at risk for developing Alzheimer’s disease

GlobeNewswire Sep 4, 2024 8:05pm
QIAGEN expands QIAstat-Dx into precision medicine through partnership for companion diagnostics in chronic diseases

GlobeNewswire Aug 28, 2024 8:05pm
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

GlobeNewswire Aug 6, 2024 8:05pm
QIAGEN delivers solid performance and exceeds outlook for Q2 2024

GlobeNewswire Jul 31, 2024 8:06pm

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.